5-Fluorouracil (5-FU) is the major chemotherapeutic component for
colorectal cancer (CRC) and other types of solid tumours. Resistance of
cancer cells to
5-FU is considered the major obstacle for successful
chemotherapy.
NF-kappaB is a
transcription factor.
Cancer cells with high
NF-kappaB nuclear activity demonstrate robust chemo- and radio-resistance. We demonstrated that nuclear
NF-kappaB activity in CRC cell lines, DLD-1 and RKO(WT), was significantly induced by
5-FU in a concentration- and time-dependent manner.
5-FU induced
IkappaBalpha degradation and promoted both
NF-kappaB nuclear translocation and its
DNA binding activity.
5-FU treatment did not influence the activities of
AP-1, AP-2, Oct-1, SP-1, CRE-B and
TFIID.
Disulfiram (DS), a clinically used anti-
alcoholism drug, strongly inhibited constitutive and 5-FU-induced
NF-kappaB activity in a dose-dependent manner. DS inhibited both
NF-kappaB nuclear translocation and
DNA binding activity but had no effect on 5-FU-induced
IkappaBalpha degradation. Used in combination, DS significantly enhanced the apoptotic effect of
5-FU on DLD-1 and RKO(WT) cell lines and synergistically potentiated the cytotoxicity of
5-FU to both cell lines. DS also effectively abolished
5-FU chemoresistance in a
5-FU resistant cell line H630(5-FU) in vitro. As DS has extensive preclinical and clinical experience, translating its anticancer usage from in vitro study to clinical trials is relatively straightforward.